ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1402

Addressing Unmet Needs in Cannabis and Hemp by Improving Knowledge and Data Collection

Jahan Marcu1, Philip Molloy2, Kayla Pray3 and Teresa Simon4, 1Marcu Enterprises/ Physicians Research Center, Jersey City, NJ, 2Physicians Research Center,LLC, Carver, MA, 3Physicians Research Center,LLC, Farmingdale, NJ, 4Physicians Research Center,LLC, Toms River, NJ

Meeting: ACR Convergence 2024

Keywords: Clinical practice guidelines, Education, Health Care, Patient reported outcomes, Surveys

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Research Methodology Poster – ARP

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Cannabis and its derivatives are increasingly integrated into treatments for rheumatic diseases, yet there is a significant lack of evidence and systematic data collection regarding their use and impact. As the prevalence and diversity of cannabinoid-containing products rise globally, gathering useful Real-World Data (RWD) becomes increasingly complex. The National Institute on Drug Abuse (NIDA) has emphasized the urgent need for harmonizing data collection. Additionally, Health Care Professionals (HCPs) often hesitate to record cannabis use data due to perceived legal challenges. This lack of systematic learning and documentation hinders understanding of the benefits, risks, and potential Drug-Drug Interactions (DDIs) associated with these products, which is crucial for informed healthcare decisions in rheumatic disease management. This abstract addresses the unmet educational needs and improve HCPs’ knowledge, attitudes (K/A), and data collection practices related to Cannabis and Cannabis-Derived Products (CCDP), including hemp and hemp-derived products.

Methods: We conducted a preliminary survey with HCPs, evaluating their K/A of CCDPs through a 40-question survey. Building on these insights, we developed a pilot study that included an updated K/A survey integrated with the Cerium educational platform. The Cerium platform features four educational modules, blogs, a virtual journal club, and discussions on patient-reported outcomes (PROs). Budsinfo, a systematic data collection tool, was integrated to report and analyze real-time outcomes related to CCDP use from participating HCPs. Follow-up surveys and discussions are conducted at virtual monthly meetings to ensure continuous learning and adaptation.

Results: Preliminary findings show that 90.9% of HCPs are open to using tools to assess patients’ cannabis experiences. However, 57.89% found the use of a self-reported Substances Use Scale App “Not applicable,” indicating barriers such as lack of access to technology and training. Additionally, 63.16% found encouraging patients to use an adverse effect reporting tool “Not applicable,” highlighting systemic barriers in patient engagement. Most HCPs rely on news and social media for cannabis information, while preferring lectures and medical journals for other new medications. Notably, over 57% of respondents reported a lack of confidence in their out current knowledge of cannabinoid molecules, underscoring the need for enhanced education and systematic data collection. And over 47% responded “not applicable” to the question, “How would you react if a patient asks you about using medical marijuana?”

Conclusion: Budsinfo and Cerium constitute a potentially comprehensive solution to bridge critical gaps in adverse event reporting and promote data-driven decision-making for regulatory agencies, HCPs, and the public. This holistic approach, combining real-time data collection with dedicated educational resources, contributes to enhanced product safety understanding and consumer health in rapidly evolving markets. By implementing these tools, we can better support healthcare providers, ultimately improving patient care and outcomes.

Supporting image 1

Supporting image 2

HCP Questionnaire: Please scan to contribute to this research.

Supporting image 3

Adverse Effect Tool


Disclosures: J. Marcu: None; P. Molloy: None; K. Pray: None; T. Simon: Bristol-Myers Squibb(BMS), 2, Janssen, 2.

To cite this abstract in AMA style:

Marcu J, Molloy P, Pray K, Simon T. Addressing Unmet Needs in Cannabis and Hemp by Improving Knowledge and Data Collection [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/addressing-unmet-needs-in-cannabis-and-hemp-by-improving-knowledge-and-data-collection/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/addressing-unmet-needs-in-cannabis-and-hemp-by-improving-knowledge-and-data-collection/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology